PH12021550033A1 - Tumor reduction formulations and methods of use thereof - Google Patents

Tumor reduction formulations and methods of use thereof

Info

Publication number
PH12021550033A1
PH12021550033A1 PH12021550033A PH12021550033A PH12021550033A1 PH 12021550033 A1 PH12021550033 A1 PH 12021550033A1 PH 12021550033 A PH12021550033 A PH 12021550033A PH 12021550033 A PH12021550033 A PH 12021550033A PH 12021550033 A1 PH12021550033 A1 PH 12021550033A1
Authority
PH
Philippines
Prior art keywords
methods
tumor reduction
formulations
reduction formulations
relates
Prior art date
Application number
PH12021550033A
Other languages
English (en)
Inventor
Steven Hoffman
John Rothman
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of PH12021550033A1 publication Critical patent/PH12021550033A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PH12021550033A 2018-07-09 2021-01-06 Tumor reduction formulations and methods of use thereof PH12021550033A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862695613P 2018-07-09 2018-07-09
PCT/US2019/040264 WO2020023191A1 (en) 2018-07-09 2019-07-02 Tumor reduction formulations and methods of use thereof

Publications (1)

Publication Number Publication Date
PH12021550033A1 true PH12021550033A1 (en) 2021-09-20

Family

ID=75267393

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550033A PH12021550033A1 (en) 2018-07-09 2021-01-06 Tumor reduction formulations and methods of use thereof

Country Status (11)

Country Link
EP (1) EP3820482A4 (de)
JP (1) JP2021530482A (de)
KR (1) KR20220098082A (de)
CN (1) CN112584841A (de)
AU (1) AU2019309757A1 (de)
BR (1) BR112021000279A8 (de)
CA (1) CA3105717A1 (de)
EA (1) EA202190201A1 (de)
IL (1) IL280000A (de)
PH (1) PH12021550033A1 (de)
WO (1) WO2020023191A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202193111A1 (ru) 2019-05-14 2022-02-10 Тайм, Инк. Композиции и способы для лечения рака
AU2020401131A1 (en) * 2019-12-09 2022-07-14 Tyme, Inc. Pharmaceutical compositions and methods
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005209243A1 (en) * 2004-01-29 2005-08-11 Baxter Healthcare S.A. Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
WO2006099685A1 (en) * 2005-03-24 2006-09-28 Medical Therapies Limited Method for the prophylaxis or treatment of carcinomas
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
EP3169707B1 (de) * 2014-07-11 2020-12-02 The Regents of the University of California Tumorselektive makropinozytose-abhängige schnell internalisierende antikörper
US9687528B2 (en) * 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations
CN109195601A (zh) * 2016-03-15 2019-01-11 迪美公司 用于治疗癌症的药物组合物

Also Published As

Publication number Publication date
BR112021000279A8 (pt) 2021-04-20
KR20220098082A (ko) 2022-07-11
AU2019309757A1 (en) 2021-03-04
BR112021000279A2 (pt) 2021-04-06
EP3820482A4 (de) 2022-03-23
IL280000A (en) 2021-03-01
CA3105717A1 (en) 2020-01-30
JP2021530482A (ja) 2021-11-11
EP3820482A1 (de) 2021-05-19
CN112584841A8 (zh) 2021-06-18
WO2020023191A1 (en) 2020-01-30
EA202190201A1 (ru) 2021-04-09
CN112584841A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
MX2023010042A (es) Polinucleotidos moduladores.
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
PH12021550033A1 (en) Tumor reduction formulations and methods of use thereof
IL278829A (en) The compositions containing bis-(fluoroalkyl)-1,4 benzodiazepines and immunotherapeutic substances and methods of using them
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MX2017011521A (es) Composiciones topicas que comprenden un corticosteroide.
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
IL272834A (en) Compositions of amantadine, their preparation, and methods of use
IL282939A (en) Mixtures and preparations containing 5-fluoro-4-imino-3-methyl-1-tosyl-4,3-dihydropyrimidin-2-one and methods of using them
ZA202000354B (en) Novel braf inhibitors and use thereof for treatment of cutaneous reactions
PH12016501838A1 (en) Compounds and their methods of use
MX2021000314A (es) Formulaciones reductoras de tumores y metodos de uso de las mismas.
MX2021006977A (es) Anellosomas y metodos de uso.
SG11202011041YA (en) Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
EP3615020A4 (de) Verfahren, mittel und zusammensetzungen zur behandlung von akuter myeloischer leukämie
EP3600277A4 (de) Zusammensetzungen zur behandlung von arzneimittelresistenten tumoren und verfahren zur verwendung davon
GB201915828D0 (en) Compounds, compositions and therapeutic uses thereof
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
EP4135687A4 (de) Polycannabinoiden, verbindungen, zusammensetzungen und verfahren zur verwendung